Guardant Health (GH) Q4 2025 earnings review
Shield Explodes, Biopharma Cools Down
Guardant delivered a blockbuster Q4 with 39% YoY revenue growth, driven by a massive acceleration in its Screening segment (Shield). Shield revenue jumped to $35.1M (up from $24.1M in Q3), confirming a breakout launch curve. However, the narrative is not flawless: the high-margin Biopharma & Data segment decelerated significantly to single-digit growth (+9%). While the company is successfully actively reducing cash burn (FCF burn improved to $54M), the divergence between the rocketing clinical business and the slowing biopharma partner business creates a mixed quality of earnings.
🐂 Bull Case
Screening revenue accelerated sequentially from $24.1M in Q3 to $35.1M in Q4. Volume hit 38,000 tests (vs 24,000 in Q3). The 2026 guidance for Screening ($162-$174M) implies a doubling of FY25 revenue, validating the 'blockbuster' narrative.
The mature Oncology segment (Guardant360) is not just stable; it's growing aggressively. Revenue grew 30% YoY, and volumes were up 38%. This proves the 'Smart Liquid Biopsy' strategy is taking share from tissue.
🐻 Bear Case
Biopharma & Data revenue growth collapsed to 9% YoY in Q4, down from 18% in Q3 and 28% in Q2. This high-margin segment is crucial for funding the cash burn of the clinical launch, and the slowdown is a major red flag.
Despite improvements, GH burned $54.2M in FCF in Q4 and guides for ~$190M burn in FY26. While the balance sheet is strong ($1.3B cash), the company remains years away from GAAP profitability (Net Loss $128.5M in Q4).
⚖️ Verdict: 🟢
Bullish. The successful scaling of Shield (Screening) is the single most important value driver for the stock, and Q4 data confirms a 'J-curve' adoption. The Biopharma slowdown is a concern, but the sheer momentum in the Clinical business (Oncology + Screening) outweighs it.
Key Themes
Screening (Shield) Hyper-Growth
Shield is outperforming even optimistic expectations. Q4 revenue of $35.1M implies an annualized run rate of ~$140M, up from ~$100M run rate in Q3. The sequential volume growth (24k to 38k tests) proves that commercial execution and health system integrations (West Virginia, Georgia) are working efficiently.
Biopharma & Data Deceleration
Decelerating. A distinct negative trend has formed. Biopharma revenue growth slowed to 9% in Q4 ($54M), marking three consecutive quarters of deceleration (28% -> 18% -> 9%). 2026 guidance calls for 'low double-digit' growth, suggesting Q4 might have been a trough, but the volatility in this high-margin partner business is a risk to the path to profitability.
Margin Expansion
Accelerating. Non-GAAP Gross Margin hit 66% in Q4 (vs 63% YoY) and 66% for the full year. This expansion is critical as it proves the company can scale Shield volumes without diluting margins. 2026 guidance (64-65%) suggests some conservatism or mix-shift pressure as Screening (lower initial margin) becomes a larger piece of the pie.
Oncology Volume & Share Gains
Stable/Growth. The core clinical business is not slowing down. Oncology test volume grew 38% YoY in Q4 (79k tests), outpacing revenue growth of 30%. This suggests some ASP pressure or mix shift, but confirms Guardant is deepening penetration in a competitive market.
OpEx Inflation
Operating expenses jumped to $302.6M in Q4 (vs $250.2M YoY). While expected due to the Shield commercial rollout, the 2026 guidance for OpEx ($1.03-1.05B) implies costs will remain elevated, growing 14-16%. The company is spending heavily to buy growth.
Other KPIs
Strong. The company has a massive runway. With a guided burn of ~$190M for 2026, they have nearly 7 years of cash at current burn rates, removing near-term dilution risk.
Improving. Burn reduced from $(83.4)M in the prior year period. The trend is positive, but the company remains in investment mode.
Accelerating. Up from 6,400 in Q4'24 and 24,000 in Q3'25. This exponential volume ramp is the primary thesis for the stock right now.
Guidance
Decelerating (optically). The midpoint implies ~28.5% YoY growth, down slightly from FY25's 33% and Q4's 39%. However, adding ~$280M in new revenue is substantial at this scale.
Accelerating. Implies >100% growth from FY25's $79.7M. This confirms Shield is the primary growth engine for the next fiscal year.
Stable/Improving. An improvement from the $(233)M burn in FY25. Shows operating leverage is kicking in, albeit slowly due to commercial reinvestment.
Decelerating. Slight moderation from the 30% growth seen in Q4 2025, likely due to the law of large numbers as the segment approaches $1B in annual revenue.
Key Questions
Biopharma Softness
Biopharma growth decelerated sharply to 9% in Q4. Is this a structural slowdown in partner spending or lumpiness in milestone payments? What gives confidence in the 'low double-digit' guide for 2026?
Shield ASP Dynamics
Screening revenue of $35.1M on 38k tests implies an ASP of ~$920. With 2026 guidance of $162-174M on 210-225k tests, the implied ASP drops to ~$770. Is this purely mix shift to commercial payers, or are there pricing pressures?
OpEx Leverage
OpEx is guided to grow 14-16% in 2026. At what revenue level does the sales force expansion stabilize, allowing for more significant drop-through to the bottom line?